Ligelizumab (Genetical Recombination)



Ligelizumab is a recombinant anti-human IgE monoclonal antibody, the complementarity-determining regions of which are derived from mouse antibody and other regions are derived from human IgG1. Ligelizumab is produced in Chinese hamster ovary cells. Ligelizumab is a glycoprotein (molecular weight: ca. 150,000) composed of 2 H-chains (γ1-chains) consisting of 453 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1322627-61-1]